Program
7MW3711 for injection
Also written as “7MW3711”.
Its studies are led by Mabwell (Shanghai) Bioscience.
Furthest: phase 3, since Sep 4, 20263 company-led studies, 3 open or runningNext primary completion: Mar 2029 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience | 33 open or running | phase 3since Sep 4, 2026 | Aug 7, 2023 | Mar 2029phase 3 · NCT07831863 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 7, 2023First studies: 2 phase 2 studies in Advanced Solid TumorFirst studyNCT06008379, NCT06008366
- Sep 4, 2026Phase 3 study in Lung Squamous Cell CarcinomaPhase 3 reachedNCT07831863 · 600 planned · China
Ahead
- Mar 2029Primary completion: phase 3 study in Lung Squamous Cell CarcinomaNCT07831863
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07831863Lung Squamous Cell Carcinoma · China | 3 | Not yet recruiting | Mar 2029 | 600 |
| NCT06008379Advanced Solid Tumor · China | 2 | Recruiting | Aug 30, 2025 | 164 |
| NCT06008366Advanced Solid Tumor · China | 2 | Recruiting | Aug 30, 2025 | 281 |
How it is read
Names in the registry
- “7MW3711 for injection”, 4 entries
- “7MW3711”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.